Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.59 |
| ▸ | PSMB1 | P20618 | 4/20 | 0.56 |
| ▸ | PSMB5 | P28074 | 4/20 | 0.56 |
| ▸ | PSMB2 | P49721 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.52 |
| ▸ | LTA4H | P09960 | 2/20 | 0.51 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.51 |
| ▸ | KDR | P35968 | 2/20 | 0.50 |
| ▸ | FLT3 | P36888 | 1/20 | 0.49 |
| ▸ | ESR1 | P03372 | 1/20 | 0.48 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21296757 | 0.85 | HRH3 (0.57) | HRH3PSMB1PSMB5PSMB2KDM4E | |
| SCHEMBL29937951 | 0.82 | HRH3 (0.61) | HRH3KDM4ERXFP1 | |
| SCHEMBL21296764 | 0.80 | HRH3 (0.58) | HRH3KDM4ERXFP1 | |
| SCHEMBL24213904 | 0.79 | PSMB1 (0.51) | HRH3PSMB1PSMB5PSMB2KDM4E | |
| SCHEMBL29937768 | 0.77 | PSMB1 (0.60) | HRH3PSMB1PSMB5PSMB2KDM4E | |
| SCHEMBL29938135 | 0.77 | NPC1 (0.49) | HRH3PSMB1PSMB5MCHR1LTA4H | |
| SCHEMBL21296793 | 0.76 | KDR (0.54) | HRH3PSMB1PSMB5PSMB2KDM4E | |
| SCHEMBL22067152 | 0.75 | PSMB1 (0.72) | HRH3PSMB1PSMB5PSMB2KDM4E | |
| SCHEMBL29066028 | 0.75 | MCHR1 (0.56) | PSMB1PSMB5PSMB2KDM4EMCHR1 | |
| SCHEMBL29066027 | 0.74 | MCHR1 (0.58) | HRH3PSMB1PSMB5PSMB2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240246943-A1 | MULTIFACETED APPROACH TO NOVEL INTERLEUKIN-6 INHIBITORS | University of Florida Research Fooundation, Incorporated (US) | 2024-07-25 | — | — | US | disclosed |
| WO-2022226133-A1 | MULTIFACETED APPROACH TO NOVEL INTERLEUKIN-6 INHIBITORS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2022-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240246943-A1 | MULTIFACETED APPROACH TO NOVEL INTERLEUKIN-6 INHIBITORS | IL6, IL6ST, IL36G | HRH3 3168/4885PSMB1 3699/4885PSMB5 3347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.